Physician profile
Megan E Busch
NPI 1003234105
$10,076.50
in general payments reported to CMS, 2019-2025
39 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $337 · 2021: $1,253 · 2022: $1,678 · 2023: $1,613 · 2024: $1,691 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,287.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,468.67 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,141.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,037.25 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $821.27 | 2019-2025 | |
| Lilly USA, LLC | $764.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $664.37 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $650.57 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $431.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $358.00 | 2019-2024 | Belsomra, Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.30 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.70 | 2019-2025 | Xifaxan, Trulance |
| Supernus Pharmaceuticals, INC. | $186.55 | 2019-2023 | |
| Astellas Pharma US INC | $180.75 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $170.17 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $162.22 | 2024-2025 | Heplisav-B |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.